Option chain shows key data for Willow Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Willow Biosciences.

Willow Biosciences (OTC:CANSF) Stock, Option Chain

Willow Biosciences Inc is a Canadian biotechnology company. It has only one reportable segment engaged in developing and producing high-purity, plant-derived ingredients for consumer care, food and beverage, and pharmaceutical products. It has a geographic presence in Canada and the United states, in which it generates the majority of its revenue from the United states.

Why cannabis stocks are up today (Pixabay)

Cannabis

Earnings

News

CANSF

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) reported on Monday its financial and operating results for the three months ended June 30, 2024, reporting significantly higher revenue and reduced costs. &#34;The second quarter was marked by significant pipeline and revenue growth with the addition of the Laurus Labs strategic partnership that includes seven high-value APIs,&#34; Dr. Chris Savile, Willow&#39;s president and CEO, said. &#34;In addition, the Company further strengthened its balance sheet by launching a private placement in June, which closed after the end of the quarter, and continued on its path to further increase efficiency and reduce costs.&#34;

CBG Producer Willow Biosciences Reports Record Q2 Revenue, Enters Major Pharma Deal Slated To Be Key Driver Of Growth

AI Generated Image 

Penny Stocks

Small Cap

Markets

Willow Biosciences Inc., (OTC: CANSF) a frontrunner in biotech innovations for sustainable ingredient production, reported its financial and operational results Tuesday morning for the fourth quarter and fiscal year 2023.

CBG Producer Willow Biosciences Announces Record 43% Revenue Increase And Strategic Moves Ahead

cannabis going up (Kindel Media by Pexels and gerald by Pixabay)

Biotech

TSX:WLLW

Biotechnology company Willow Biosciences generated around $1.3m in revenues in 2023, a 60% increase from the previous year. The company has hailed 2023 as a &#34;transformative year,&#34; citing the launch of its BioOxi bio-oxidation platform technology as one of its top achievements. The AI-driven selective hydroxylation platform removes multiple chemical steps and reduces the cost of manufacturing target molecules. The technology has enabled Willow to accelerate its path to nearer-term and potentially larger revenue opportunities while reducing operational expenses. The company also engaged in multiple partnerships with innovators and generic pharmaceutical companies, resulting in portfolio expansion and diversification. Willow underwent a restructuring of its corporate and operational framework, including consolidating operations in the San Francisco Bay area and making changes to its leadership team. In 2024, Willow plans to capitalize on the BioOxi technology platform to bring its corticosteroids program to commercial readiness and identify strategic partners for pipeline expansion and acceleration.

Company Exploring CBG Production Signals New Era Of Commercial Success In Synthetic Biology

WILLOW BIOSCIENCES INC by Willow Biosciences Inc.

Willow Biosciences Inc

Willow Biosciences Inc (CANSF) stock is lower by -22.22% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives CANSF stock a score of  0 out of a possible 100. That rank is chiefly influenced by a short-term technical score of 0. CANSF's rank also includes a long-term technical score of 0.  CANSF h

Is Willow Biosciences Inc (CANSF) Stock Worth a Buy Friday?

Willow Biosciences GAAP EPS of -C$0.10, revenue of C$1.17M

Willow Biosciences reports Q1 results; reaffirms FY24 outlook

Willow Biosciences reports Q2 results

Willow Biosciences reports Q3 results

Press Releases

WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC.

Contracts

WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT

WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WILLOW ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $2.0 MILLION

Offerings

WILLOW ANNOUNCES CANCELLATION OF PREVIOUSLY ANNOUNCED NON-BROKERED OFFERING TO PURSUE LESS DILUTIVE ALTERNATIVES

Willow Biosciences

Comments

Willow Biosciences

Willow Biosciences (CANSF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga